文献速递膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤前列腺癌

人类发展指数与全球膀胱癌、肾癌、前列腺癌及睾丸癌发病率和死亡率的关联

Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality.
PubMed 文献 · BJU Int · 2017-05-08

研究从GLOBOCAN 2012数据库获取184个国家及16个主要世界地区的年龄标化发病率和死亡率,比较男性和女性的死亡率与发病率比值(MIR),并用2014年联合国人类发展指数(HDI)评估与社会经济发展的关联。结果显示,较发达国家四种泌尿生殖系统恶性肿瘤的年龄标化发病率是较不发达国家的2.9倍(膀胱癌)至7.4倍(睾丸癌);前列腺癌、膀胱癌和肾癌的年龄标化死亡率在较发达国家是较不发达国家的1.5至2.2倍,睾丸癌死亡率无差异;HDI与MIR在睾丸癌、前列腺癌、肾癌和膀胱癌均呈强相关。

要点

  • 较发达国家膀胱癌至睾丸癌的年龄标化发病率为较不发达国家的2.9至7.4倍。
  • 前列腺癌、膀胱癌和肾癌年龄标化死亡率在较发达国家为较不发达国家的1.5至2.2倍,睾丸癌无差异。
  • HDI与MIR在睾丸癌、前列腺癌、肾癌和膀胱癌均呈强相关,较不发达国家MIR最高。

核心结论

  • 全球泌尿生殖系统肿瘤的发病率和死亡率差异很大,但四种主要泌尿生殖系统恶性肿瘤的MIR均在较不发达国家最高。
  • 需要进一步研究以了解合并症、暴露、诊断时间、医疗可及性、诊断技术或治疗选择的差异是否能解释观察到的泌尿生殖系统肿瘤结局不平等。

研究设计与样本

  • 研究从GLOBOCAN 2012数据库获取184个国家和16个主要世界地区的性别特异性年龄标化发病率和死亡率。
  • 研究比较男性和女性在国家及地区层面的死亡率与发病率比值(MIR),并使用2014年联合国人类发展指数(HDI)评估与社会经济发展的关联。

主要发现

  • 较发达国家相比更不发达国家,泌尿生殖系统恶性肿瘤的年龄标化发病率为2.9倍(膀胱癌)至7.4倍(睾丸癌)。
  • 前列腺癌、膀胱癌和肾癌的年龄标化死亡率在较发达国家相比更不发达国家为1.5至2.2倍,睾丸癌死亡率无差异。
  • HDI与MIR在睾丸癌呈强相关(回归系数1.65,R²=0.78),前列腺癌(回归系数-1.56,R²=0.85),肾癌(回归系数-1.34,R²=0.74),膀胱癌(回归系数-1.01,R²=0.80)。

局限性

  • 原文结论指出需要进一步研究以了解合并症、暴露、诊断时间、医疗可及性、诊断技术或治疗选择的差异是否能解释观察到的泌尿生殖系统肿瘤结局不平等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To describe contemporary worldwide age-standardized incidence and mortality rates for bladder, kidney, prostate and testis cancer and their association with development. MATERIALS AND METHODS: We obtained gender-specific, age-standardized incidence and mortality rates for 184 countries and 16 major world regions from the GLOBOCAN 2012 database. We compared the mortality-to-incidence ratios (MIRs) at national and regional levels in males and females, and assessed the association with socio-economic development using the 2014 United Nations Human Development Index (HDI). RESULTS: Age-standardized incidence rates were 2.9 (bladder) to 7.4 (testis) times higher for genitourinary malignancies in more developed countries compared with less developed countries. Age-standardized mortality rates were 1.5-2.2 times higher in more vs less developed countries for prostate, bladder and kidney cancer, with no variation in mortality rates observed in testis cancer. There was a strong inverse relationship between HDI and MIR in testis (regression coefficient 1.65, R2 = 0.78), prostate (regression coefficient -1.56, R2 = 0.85), kidney (regression coefficient -1.34, R2 = 0.74), and bladder cancer (regression coefficient -1.01, R2 = 0.80). CONCLUSION: While incidence and mortality rates for genitourinary cancers vary widely throughout the world, the MIR is highest in less developed countries for all four major genitourinary malignancies. Further research is needed to understand whether differences in comorbidities, exposures, time to diagnosis, access to healthcare, diagnostic techniques or treatment options explain the observed inequalities in genitourinary cancer outcomes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Greiman AK, Rosoff JS, Prasad SM, et al. Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality. BJU Int. 2017. PMID: 28480994. doi:10.1111/bju.13875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。